Aspasia Stamatoullas
Aspasia Stamatoullas is an expert in Hematology at Centre Henri Becquerel (France). As of October 2026, ScienceLeadR ranks Aspasia Stamatoullas in the top 1% of experts worldwide for Lymphoma and Lymphoproliferative Disorders. Aspasia Stamatoullas has authored 315 publications, the most recent in 2026, and is an investigator in 28 clinical trials, 3 of them ongoing. SLR score: 1,004 (community average: 125). How the SLR is computed.
LeadR Profile
Hematology
Subspecialties: Oncology - Immunology - Cardiology
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 1992 - 2026
Number : 315
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
Clinical Studies 28
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Cohort/Consortium Investigators 2
Ongoing Clinical Trials
3 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| Cohort of Patients With Chronic Myelomonocytic Leukemia NCT07512882 — bone marrow, blood, surgical procedures, operative, leukemia, myelomonocytic, chronic, leukemia, research, edetic acid, tissues, surgeons, bone and bones | N/A | Recruiting | 2026 |
| Venetoclax in Patients With MDS or AML in Relapse After AHSCT NCT05226455 — cells, microscopy, electron, scanning transmission, lymphocytes, stem cells, azacitidine, cell transplantation, stem cell transplantation, transplantation | Phase 1/Phase 2 | Active not recruiting | 2022 |
| Study Evaluating Combination of Luspatercept in LR MDS Without RS Having Failed or Being Ineligible to ESA NCT05181735 — injections, epoetin alfa, myelodysplastic syndromes, injections, subcutaneous | Phase 1/Phase 2 | Recruiting | 2022 |
LeadR Networks
Main global connection map